RecruitingPhase 2NCT06931405

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

Sponsor

Blueprint Medicines Corporation

Enrollment

105 participants

Start Date

May 28, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Inducible Urticaria Chronic Spontaneous Urticaria

Summary

This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BLU-808 and a drug called Placebo for people with chronic inducible urticaria and chronic spontaneous urticaria. The study is currently recruiting participants at 47 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBLU-808

Oral administration

DRUGPlacebo

Oral administration

Locations(47)

Allervie Clinical Research

Birmingham, Alabama, United States

Acuro Research, Inc.

Little Rock, Arkansas, United States

Modena Allergy & Asthma Clinical Research - La Jolla

La Jolla, California, United States

Allergy & Asthma Associates of Southern California

Laguna Niguel, California, United States

Allergy & Asthma Medical Group and Research Center

San Diego, California, United States

Allergy Affiliates Inc.

Bradenton, Florida, United States

University of South Florida

Tampa, Florida, United States

Treasure Valley Medical Research

Boise, Idaho, United States

Endeavor Health

Northbrook, Illinois, United States

Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, United States

Southern Indiana Clinical Trials

New Albany, Indiana, United States

The Indiana Clinical Trials Center

Plainfield, Indiana, United States

Equity Medical - Bowling Green

Bowling Green, Kentucky, United States

Johns Hopkins University

Baltimore, Maryland, United States

Institute For Asthma & Allergy

Wheaton, Maryland, United States

Chesapeake Clinical Research

White Marsh, Maryland, United States

Henry Ford Health

Detroit, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

The Clinical Research Center LLC.

St Louis, Missouri, United States

Montana Medical Research, Inc.

Missoula, Montana, United States

Equity Medical (at Cameron Dermatology) - New York

New York, New York, United States

Bernstein Clinical Research Center

Cincinnati, Ohio, United States

Allergy & Clinical Immunology Associates

Pittsburgh, Pennsylvania, United States

National Allergy, Asthma & Urticaria Centers of Charleston

Charleston, South Carolina, United States

Medical University of South Carolina (MUSC)

Charleston, South Carolina, United States

Reveal Research Institute

Dallas, Texas, United States

Austin Institute for Clinical Research

Pflugerville, Texas, United States

Odense University Hospital - Odense

Odense, Denmark

Fraunhofer-Institut fuer Translationale Medizin und Pharmakologie ITMP - Standort Berlin

Berlin, Germany

Universitaetsklinikum Carl Gustav Carus Dresden

Dresden, Germany

Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet

Frankfurt am Main, Germany

Medizinische Hochschule Hannover (MHH)

Hanover, Germany

Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz

Mainz, Germany

Universitaetsklinikum Tuebingen

Tübingen, Germany

Azienda Ospedale - Università Padova

Padova, Italy

Azienda Ospedaliero Universitaria Policlinico Umberto

Rome, Italy

Centro Ricerche Cliniche di Verona s.r.l.

Verona, Italy

Hospital del Mar

Barcelona, Spain

Hospital Universitario Vall d'Hebron

Barcelona, Spain

Hospital Universitari de Bellvitge

Barcelona, Spain

Hospital Regional Universitario de Malaga

Málaga, Spain

National Taiwan University Hospital Hsin-Chu Branch

Hsinchu, Taiwan

Kaohsiung Veterans General Hospital (KSVGH)

Kaohsiung City, Taiwan

Taipei Medical University - Shuang Ho Hospital

New Taipei City, Taiwan

China Medical University Hospital

Taichung, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Linkou Chang Gung Memorial Hospital (CGMHLK)

Taoyuan City, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06931405

Related Trials

A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria

NCT071813692 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

NCT07005713

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT0726640273 locations

A Trial of HRS-3095 in Healthy Volunteers

NCT07686484

Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)

NCT07642557